Holen Sie sich die Stockscreener-App
3.37
1.75%
-0.06
Handel nachbörslich:
3.37
Schlusskurs vom Vortag:
$3.43
Offen:
$3.42
24-Stunden-Volumen:
488.55K
Relative Volume:
0.53
Marktkapitalisierung:
$268.40M
Einnahmen:
$130.42M
Nettoeinkommen (Verlust:
$18.64M
KGV:
15.44
EPS:
0.2182
Netto-Cashflow:
$4.05M
1W Leistung:
-2.88%
1M Leistung:
-7.67%
6M Leistung:
-46.42%
1J Leistung:
-75.72%
1-Tages-Spanne:
$3.355
$3.515
1-Wochen-Bereich:
$3.355
$3.575
52-Wochen-Spanne:
$3.35
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Firmenname
Niagen Bioscience Inc
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
3.37 | 280.35M | 130.42M | 18.64M | 4.05M | 0.2182 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
| 2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition - Investing.com
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce - Investing.com
Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program - Yahoo Finance
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science - Business Wire
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference - Stock Titan
Is Niagen Bioscience’s (NAGE) NAD+ Research Push Quietly Redefining Its Competitive Moat? - simplywall.st
Niagen Bioscience (NAGE) Rebrands Research Program - GuruFocus
Niagen Bioscience renames research program By Investing.com - Investing.com Nigeria
Niagen Bioscience renames research program - Investing.com
Q4 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Q1 2026 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Q2 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Q3 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
NAGE Stock Price, Quote & Chart | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $10 - Moomoo
NAGE Technical Analysis | Trend, Signals & Chart Patterns | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims - The Manila Times
National Advertising Review Board Recommends Niagen Modify - GlobeNewswire
NAGE News | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience Earnings Call Highlights Growth Push - TipRanks
How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower - Yahoo Finance
Is Niagen Bioscience’s (NAGE) Telehealth Niagen Plus Launch a Turning Point in Its Direct-Access Strategy? - simplywall.st
Niagen Bioscience stock price target lowered to $11 by H.C. Wainwright - Investing.com Australia
HC Wainwright Lowers Niagen Bioscience (NASDAQ:NAGE) Price Target to $11.00 - MarketBeat
Assessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery Initiatives - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results - Post Register
Will Niagen Bioscience’s (NAGE) Telehealth NAD+ Push Redefine Its Core Therapeutic Focus? - Yahoo Finance
Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results - Streetwise Reports
Niagen Bioscience Announces Participation in Upcoming Investor Conferences - PharmiWeb.com
Niagen Bioscience Announces Participation in Upcoming May 2026 Investor Conferences - BioSpace
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition By Investing.com - Investing.com South Africa
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED) - Benzinga
Niagen Bioscience reaffirms 10%-15% 2026 growth outlook while increasing marketing spend expectations - MSN
Niagen Bioscience Inc Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce By Investing.com - Investing.com South Africa
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Niagen (NAGE) Q1 2026 Earnings Call Transcript - AOL.com
Finanzdaten der Niagen Bioscience Inc-Aktie (NAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Niagen Bioscience Inc-Aktie (NAGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.81 |
4,465 |
30,406 |
7,372 |
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.85 |
2,220 |
15,210 |
2,220 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):